THERAPY DOSSIER · th-6b9856771735

Secretome of apoptotic human peripheral blood mononuclear cells (MNC-secretome)

Biologic · Biologic (secretome of apoptotic PBMCs); not a ChEMBL entity, preclinical

Evidence & regulatory context

Mechanism: Biologic (secretome of apoptotic PBMCs); not a ChEMBL entity, preclinical
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25797576 ↗2015Reported benefit

The secretome of apoptotic human peripheral blood mononuclear cells attenuates secondary damage following spinal cord injury in rats.

RatSpinal cord injuryContusionSprague-DawleyMaleSystemic

Model: Spinal cord contusion injury

MNC-secretome improved functional recovery, reduced cavity formation and acute axonal injury, increased vascular density and CD68 recruitment, and lowered inducible nitric oxide synthase expression compared with controls.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…